John Konstantopoulos, Co-Founder and CEO of Artrya, said: "We are thrilled to have received FDA clearance of our Salix® Coronary Plaque module, which opens up a much greater revenue opportunity for us ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback